ConductScience.org, home

Paper36910854

Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.

Chen N and 2 others. Chin J Cancer Res, 2023. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment. Papers, record 36910854. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36910854

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.
PubMed
Journal
Chin J Cancer Res
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.41
iCite
Revised in PubMed
2023-03-14
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen NNan
2A Ajani JJaffer
3Wu AAiwen

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References93

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116123223
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood2005https://conductscience.org/library/papers/16123223PubMed
225167226Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.Br J Cancer2014https://conductscience.org/library/papers/25167226PubMed
312932382Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.Lancet2003https://conductscience.org/library/papers/12932382PubMed
422857859
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Radiother Oncol2012https://conductscience.org/library/papers/22857859PubMed
519631287Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma.Clin Gastroenterol Hepatol2010https://conductscience.org/library/papers/19631287PubMed
69586910Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.J Clin Oncol1998https://conductscience.org/library/papers/9586910PubMed
718407433Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.Int J Radiat Oncol Biol Phys2008https://conductscience.org/library/papers/18407433PubMed
87783535Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.Lancet1995https://conductscience.org/library/papers/7783535PubMed
921287530Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.Cancer2011https://conductscience.org/library/papers/21287530PubMed
1029861116Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.Lancet Oncol2018https://conductscience.org/library/papers/29861116PubMed
111548520Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.J Clin Oncol1992https://conductscience.org/library/papers/1548520PubMed
129112461Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications.Int J Radiat Oncol Biol Phys1997https://conductscience.org/library/papers/9112461PubMed
1326374429Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.J Natl Cancer Inst2015https://conductscience.org/library/papers/26374429PubMed
1427029228
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.
Lancet Haematol2014https://conductscience.org/library/papers/27029228PubMed
1516324817Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.Eur J Surg Oncol2006https://conductscience.org/library/papers/16324817PubMed
1615569109Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.Aliment Pharmacol Ther2004https://conductscience.org/library/papers/15569109PubMed
171682595Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma.Lancet1991https://conductscience.org/library/papers/1682595PubMed
1826742109ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Neuroendocrinology2016https://conductscience.org/library/papers/26742109PubMed
1915752894Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.Int J Radiat Oncol Biol Phys2005https://conductscience.org/library/papers/15752894PubMed
2029566109Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.JAMA Oncol2018https://conductscience.org/library/papers/29566109PubMed

See all 93 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42649986Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers (Basel)2026https://conductscience.org/library/papers/42649986PubMed
40042008Associations of Social Vulnerability and Race-Ethnicity With Gastrointestinal Cancers in the United States.Cancer Med2025https://conductscience.org/library/papers/40042008PubMed
39958355A preoperative predictive model based on multi-modal features to predict pathological complete response after neoadjuvant chemoimmunotherapy in esophageal cancer patients.Front Immunol2025https://conductscience.org/library/papers/39958355PubMed
38751434Distal margin distance in radical resection of locally advanced rectal cancer after neoadjuvant therapy.Chin J Cancer Res2024https://conductscience.org/library/papers/38751434PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36910854

GET https://conductscience.org/api/papers/v1/36910854/references?page=2